Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of “Moderate Buy” by Analysts

Neurogene Inc. (NASDAQ:NGNE) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $44.00.

A number of equities research analysts have recently issued reports on NGNE shares. Canaccord Genuity Group assumed coverage on shares of Neurogene in a report on Friday, February 27th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Lifesci Capital began coverage on shares of Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Neurogene in a report on Tuesday, January 13th. Finally, Wall Street Zen lowered shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th.

Institutional Investors Weigh In On Neurogene

Several large investors have recently added to or reduced their stakes in NGNE. Schroder Investment Management Group purchased a new stake in shares of Neurogene in the 2nd quarter valued at about $451,000. PNC Financial Services Group Inc. grew its holdings in shares of Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after purchasing an additional 1,232 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Neurogene during the fourth quarter worth about $165,000. Jennison Associates LLC increased its position in shares of Neurogene by 35.3% in the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after purchasing an additional 138,999 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in shares of Neurogene in the third quarter worth approximately $223,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Stock Up 6.5%

NGNE stock opened at $23.60 on Tuesday. The firm has a market capitalization of $365.56 million, a PE ratio of -5.74 and a beta of 1.53. Neurogene has a twelve month low of $6.88 and a twelve month high of $37.27. The stock has a 50-day simple moving average of $18.92 and a two-hundred day simple moving average of $21.54.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.